Publications

1. Lodewijk J.A. Toonen, Frank Rigo, Haico van Attikum, Willeke M.C. van Roon-Mom. Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice. Molecular Therapy Nucleic Acids (2017) (8): 232-242. Impact Factor: 6.392

2. Menno H. Schut, Stefano Patassini, Eric H. Kim, Jocelyn Bullock, Henry J. Waldvogel, Richard L.M. Faull, Barry A. Pepers, Johan T. den Dunnen, Gert-Jan B. van Ommen, and Willeke M.C. van Roon-Mom. Effect of Post-Mortem Delay on N-terminal Huntingtin Protein Fragments in Human Control and Huntington Disease Brain Lysates. PlosOne May (2017), Jun 1;12(6):e0178556. doi: 10.1371/journal.pone.0178556. Impact Factor: 4.4

3. Caroline Godfrey, Lourdes R Desviat, Bård Smedsrød, France Piétri-Rouxel, Michela A. Denti, Petra Disterer, Stéphanie Lorain, Gisela Nogales-Gadea, Valentina Sardone, Rayan Anwar, Samir El Andaloussi, Taavi Lehto, Bernard Khoo, Camilla Brolin, Willeke M.C. van Roon-Mom, Aurélie Goyenvalle, Annemieke Aartsma-Rus, Virginia Arechavala-Gomeza. Delivery is key: lessons learnt from developing splice switching antisense therapies. EMBO Molecular Medicine (2017) DOI 10.15252/emmm.201607199 e201607199. Impact Factor: 9.508

4. G. Stuitje, M.J. van Belzen, S.L. Gardiner, W.M.C. van Roon-Mom, M.W. Boogaard; REGISTRY Investigators of the European Huntington Disease Network, S.J. Tabrizi, R.A.C. Roos, N.A. Aziz. Age of onset in Huntington's disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes. Brain (2017) Jul 1;140(7):doi: 10.1093/brain/awx122. Impact Factor: 10.545

5. Nasir Aziz, Sarah Gardiner, Martine van Belzen, Merel Boogaard, Willeke van Roon-Mom, Maarten Rozing, Albert van Hemert, Johannes H. Smit, Aartjan Beekman, Gerard van Grootheest, Robert Schoevers, Richard Oude Voshaar, Raymund Roos, Hannie Comijs, Brenda W.J.H. Penninx, and Roos van der Mast. Huntingtin gene repeat size variations affect risk of lifetime depression. Translational Psychiatry Dec (2017) Dec 11;7(12):1277. Impact Factor: 13.328

6. Lodewijk J.A. Toonen, Iris Schmidt, Martijn S. Luijsterburg, Haiko van Attikum, Willeke M.C. van Roon-Mom. Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3. Scientific Reports (2016) Oct 12;6:35200. doi: 10.1038/srep35200. Impact Factor: 5.525  

7. M.M. Evers, M.H. Schut, B.A. Pepers, M. Atalar, M.J. van Belzen, R.L.M. Faull, R.A.C. Roos, W.M.C. van Roon-Mom. Making (anti-) sense out of huntingtin levels in Huntington disease. Molecular Neurodegeneration (2015), doi: 10.1186/s13024-015-0018-7. Impact Factor: 6.560

8. A.Mastrokolias ,Y.Ariyurek, J.J. Goeman, E. van Duijn, R.A.C.Roos, R.C. van der Mast, G.J.B. van Ommen, J.T. den Dunnen, P.A.C. ’t Hoen, W.M.C. van Roon-Mom. Next generation sequencing gene expression profiling of peripheral blood samples identifies a robust Huntington’s disease signature. European Journal of Human Genetics (2015) 23(10):1349-56. Impact Factor: 4.225

9. M.M. Evers, L.J.A. Toonen, W.M.C. van Roon-Mom. Antisense oligonucleotides in therapy for neurodegenerative disorders. Advanced Drug Delivery Reviews (2015) Jun 29;87:90-103. Impact Factor: 12.707

10. M.A. Curtis, M. Kam, U. Nannmark, M.F. Anderson, M. Zetterstrom Axell, C. Wikkelso, S. Holtås, W.M.C. van Roon-Mom, T. Björk-Eriksson, C. Nordborg, J. Frisén, M. Dragunow, R.L.M. Faull, P.S. Eriksson. Human Neuroblasts Migrate to the Olfactory Bulb via a Lateral Ventricular Extension. Science (2007) Vol 315, 2 March:1243-1249. Impact Factor: 29.7

All publications